JERICHO, N.Y., June 11, 2026 (GLOBE NEWSWIRE) -- Kimco Realty® (NYSE: KIM) today announced that its operating subsidiary, Kimco Realty OP, LLC (“Kimco OP”), priced its offering of $525,000,000 aggregate principal amount of 3.50% exchangeable senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $500,000,000 aggregate principal amount of notes. Kimco Realty Corporation (“Kimco”) will fully and unconditionally guarantee the notes on a senior, unsecured basis. The issuance and sale of the notes are scheduled to settle on June 15, 2026, subject to customary closing conditions. Kimco OP also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $75,000,000 principal amount of notes.
Creates a premier, global powertrain leader focused on commercial and light vehicles with approximately $11 billion in sales and approximately $1.7 billion adjusted EBITDA...
Mid-year update highlights strong execution across the Company's U.S. uranium operations, with an expected 1.6 million pounds of finished U3O8 produced from January through...
Mid-year update highlights strong execution across the Company's U.S. uranium operations, with an expected 1.6 million pounds of finished U3O8 produced from January through...
Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...
CALGARY AB, June 10, 2026 /CNW/ - InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) ("InPlay" or the "Company") announced today the voting results for the election of directors at its...
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.
In the news release, The Galien Foundation Announces 2026 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical...
KNOXVILLE, TN, June 10, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (“SafeSpace Global” or the “Company”), a provider of AI-powered physical safety and security solutions for regulated care environments, today announced the launch of its new Addiction Treatment Vertical, supported by a newly executed Master Services Agreement (“MSA”) with Antidote Health Ventures and a conditional funding commitment from Method Five Labs, LLC (“Method Five Labs”).